Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients
- 30 April 2001
- journal article
- Published by Elsevier in Seminars in Hematology
- Vol. 38, 52-59
- https://doi.org/10.1016/s0037-1963(01)90109-x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- A Multicenter Study of Recombinant Factor VIII (RecombinateTM) in Previously Treated Patients with Hemophilia AThrombosis and Haemostasis, 1997
- Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIIIThe Lancet, 1993
- Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of InhibitorsNew England Journal of Medicine, 1993
- Incidence of development of factor VIII and factor IX inhibitors in haemophiliacsThe Lancet, 1992
- Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII CAnnals of Hematology, 1991
- Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia ANew England Journal of Medicine, 1990
- In vitro and in vivo Characterization of Factor VIII PreparationsVox Sanguinis, 1980
- Characteristics of Various Factor VIII Concentrates used in Treatment of Haemophilia ABritish Journal of Haematology, 1977